Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How would you treat a patient with a post prostatectomy biochemical and pelvic nodal recurrence with a BLM mutation?
Related Questions
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
How would you treat an isolated urothelial cancer local recurrence abutting the duodenum?
How do you manage prostatic adenocarcinoma after a subtotal resection?
Does long term use of 5 alpha reductase inhibitors change the way you evaluate a PSMA PET?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
Given the different rates of testosterone recovery, do you alter the duration of ADT when using Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation?
What is your preferred approach in a patient unable to fill their bladder during prostate radiotherapy?
How would you treat a patient with isolated CNS relapse of seminoma?
Would you continue serial PSMA PET scans after 2 negative scans for patients with a persistently rising PSA post-RT?
